TABLE 4.
Covariate | Univariable regression | Multivariable regression | ||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Age | 1.010 (0.970-1.052) | .634 | N/A | |
Gender | ||||
Male | Reference | — | N/A | |
Female | 1.478 (0.593-3.682) | .401 | N/A | |
Laterality | ||||
Left | Reference | — | N/A | |
Right | 1.036 (0.415-2.583) | .940 | N/A | |
Year of diagnosis | 1.009 (0.885-1.150) | .896 | N/A | |
Pretreatment serviceable hearing | ||||
Yes (Gardner-Robertson I or II) | Reference | — | N/A | |
No (Gardner-Robertson III, IV, or V) | 1.003 (0.311-3.234) | .997 | N/A | |
Pretreatment hearing loss | ||||
Yes | 1.026 (0.231-4.563) | .973 | N/A | |
No | Reference | |||
Pretreatment CN VII dysfunction | ||||
Yes | 0.044 (0.000-97.313) | .426 | N/A | |
No | Reference | |||
Pretreatment CN V dysfunction | ||||
Yes | 1.266 (0.289-5.548) | .754 | N/A | |
No | Reference | |||
Tumor size, max. diameter | 0.623 (0.253-1.533) | .303 | N/A | |
Tumor size, volume | 0.790 (0.381-1.635) | .525 | N/A | |
Tumor grade (Samii classification) | 1.069 (0.801-1.427) | .651 | N/A | |
Dose rate, median | ||||
< 2.675 Gy/min | Reference | |||
≥ 2.675 Gy/min | 1.300 (0.518-3.265) | .576 | N/A | |
Dose rate, continuous | 1.424 (0.716-2.834) | .314 | N/A | |
Prescription isodose | 0.998 (0.953-1.045) | .926 | N/A | |
Mean target dose (Gy) | 1.001 (0.912-1.097) | .991 | N/A | |
Minimum target dose (Gy) | 0.950 (0.762-1.184) | .646 | N/A | |
Maximum target dose (Gy) | 0.991 (0.913-1.076) | .838 | N/A | |
RTOG conformity index | 0.908 (0.277-2.983) | .874 | N/A | |
Paddick conformity index | 3.279 (0.023-469.685) | .639 | N/A | |
Selectivity index | 3.416 (0.031-377.991) | .609 | N/A | |
Energy index | 9.072 (0.317-259.60) | .198 | N/A | |
RTOG homogeneity index | 0.748 (0.036-15.373) | .850 | N/A |